TrialCancer immunology, immunotherapy : CII2025

Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.

Wen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.